Accéder au contenu
Merck
  • Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.

Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.

The Journal of biological chemistry (2007-02-08)
Mihaela Necula, Rakez Kayed, Saskia Milton, Charles G Glabe
RÉSUMÉ

Alzheimer disease is characterized by the abnormal aggregation of amyloid beta peptide into extracellular fibrillar deposits known as amyloid plaques. Soluble oligomers have been observed at early time points preceding fibril formation, and these oligomers have been implicated as the primary pathological species rather than the mature fibrils. A significant issue that remains to be resolved is whether amyloid oligomers are an obligate intermediate on the pathway to fibril formation or represent an alternate assembly pathway that may or may not lead to fiber formation. To determine whether amyloid beta oligomers are obligate intermediates in the fibrillization pathway, we characterized the mechanism of action of amyloid beta aggregation inhibitors in terms of oligomer and fibril formation. Based on their effects, the small molecules segregated into three distinct classes: compounds that inhibit oligomerization but not fibrillization, compounds that inhibit fibrillization but not oligomerization, and compounds that inhibit both. Several compounds selectively inhibited oligomerization at substoichiometric concentrations relative to amyloid beta monomer, with some active in the low nanomolar range. These results indicate that oligomers are not an obligate intermediate in the fibril formation pathway. In addition, these data suggest that small molecule inhibitors are useful for clarifying the mechanisms underlying protein aggregation and may represent potential therapeutic agents that target fundamental disease mechanisms.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Bromure d'hexadécyltriméthylammonium, ≥98%
Sigma-Aldrich
Bromure d'hexadécyltriméthylammonium, for molecular biology, ≥99%
Sigma-Aldrich
Melatonin, powder, ≥98% (TLC)
Sigma-Aldrich
Bromure d'hexadécyltriméthylammonium, BioXtra, ≥99%
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Neocuproine, ≥98%
Sigma-Aldrich
Apigenin, ≥95.0% (HPLC)
Sigma-Aldrich
Bromure d'hexadécyltriméthylammonium, BioUltra, for molecular biology, ≥99.0% (AT)
Sigma-Aldrich
o-Vanillin, 99%
Sigma-Aldrich
Bromure de myristyltriméthylammonium bromide, ≥99%
Sigma-Aldrich
Tetrahydrothiophène, 99%
Sigma-Aldrich
Myricetin, ≥96.0% (HPLC)
Sigma-Aldrich
Myricetin, ≥96.0%, crystalline
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
5-Hydroxy-1,4-naphthoquinone, 97%
Sigma-Aldrich
Nordihydroguaiaretic acid, ≥97.0% (HPLC)
Sigma-Aldrich
Phenol red solution, 0.5%, liquid, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Phenol Red, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Eosin Y solution, 5 wt. % in H2O
Sigma-Aldrich
Phenol Red, ACS reagent
Sigma-Aldrich
Eosin Y disodium salt, certified by the Biological Stain Commission
Sigma-Aldrich
Eosin Y disodium salt, Dye content ≥85 %
Sigma-Aldrich
Bromure d'hexadécyltriméthylammonium, ≥96.0% (AT)
Supelco
Bromure d'hexadécyltriméthylammonium, suitable for ion pair chromatography, LiChropur
Sigma-Aldrich
Bromure de myristyltriméthylammonium bromide, 98% (AT)
Supelco
Bromure d'hexadécyltriméthylammonium, analytical standard
Supelco
Bromure de myristyltriméthylammonium bromide, suitable for ion pair chromatography, LiChropur, ≥99.0% (AT)